Citigroup released a research report stating that Hengrui Pharmaceuticals' target prices for H shares and A shares were raised by 0.8% and 1.8% to HK$120 and RMB 111, respectively. Hengrui Pharmaceuticals is still one of the bank's preferred key recommended targets.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.